Argonaut Therapeutics is a precision therapeutics company that was established to develop epigenetically-acting drugs which target abnormal arginine methylation in cancer. The company was founded on pioneering research from the University of Oxford, UK. Argonaut strives to develop a new class of precision cancer medicines which target the enzymes responsible for abnormal arginine methylation in cancer.